{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"2"}],"units":"Participants"}],"description":"An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). A TEAE was defined as any adverse event either reported for the first time or the worsening of a pre-existing event after the first dose of study drug and within 30 days of the last dose of study drug.","groups":[{"description":"Participants with fibroblast growth factor (FGF) receptor 2 (FGFR2) rearrangements or fusions self-administered oral pemigatinib at a starting dose of 13.5 milligrams (mg) once daily (QD) on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.","id":"OG000","title":"Cohort A: FGFR2 Rearrangements or Fusions"},{"description":"Participants with all other FGF/FGFR alterations self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.","id":"OG001","title":"Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions"},{"description":"Participants with no FGF/FGFR alterations self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles (United States only). Pemigatinib was administered until documented disease progression or unacceptable toxicity.","id":"OG002","title":"Cohort C: Negative for FGF/FGFR Alterations"},{"description":"Participants with an FGF/FGFR status for whom the local laboratory FGF/FGFR results could not be confirmed centrally self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.","id":"OG003","title":"Other"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population: all enrolled participants who received at least 1 dose of pemigatinib","reportingStatus":"POSTED","timeFrame":"up to 1584 days","title":"Number of Participants With Any Treatment-emergent Adverse Event (TEAE)","type":"SECONDARY","unitOfMeasure":"Participants"}